Request Your Free White Paper Now:

"How combining datasets from multiple sources can inform and improve commercial strategies"

Using claims data alone can jeopardize a drug’s launch, especially in rare diseases. Fill the blind spots with better data using this essential guide.

Hundreds of rare disease treatments have entered the market over the past decade—thanks largely to a combination of government incentives, strong urging from patient advocacy groups and advances in cell and gene therapies.

But despite the supportive landscape for rare disease therapies, pharma companies still struggle to launch on time, if at all. Is the data to blame?

In this white paper, you’ll learn:

• How real-world datasets that rely only on claims can create blind spots and limit commercial strategy
• Underused data sources to consider, such as lab reports and EHRs
• Best practices to strengthen real-world data with integrative linking
• What to look for when sourcing fit-for-purpose real-world data

Offered Free by: Komodo Health
See All Resources from: Komodo Health